{
    "organizations": [],
    "uuid": "feb1ed5a053a75b978974269bf3933bafa6a1d24",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-grants-breakthrough-therapy-de/brief-fda-grants-breakthrough-therapy-designation-for-pfizers-tafamidis-idUSASC0A3D6",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Grants Breakthrough Therapy Designation For Pfizer's Tafamidis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - Pfizer Inc:\n* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR TAFAMIDIS FOR THE TREATMENT OF PATIENTS WITH TRANSTHYRETIN CARDIOMYOPATHY\n* PFIZER INC - DECISION IS SUPPORTED BY TOPLINE RESULTS FROM TAFAMIDIS PHASE 3 TRANSTHYRETIN CARDIOMYOPATHY (ATTR-ACT) STUDY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-23T20:32:00.000+03:00",
    "crawled": "2018-05-24T20:11:55.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "pfizer",
        "inc",
        "fda",
        "grant",
        "breakthrough",
        "therapy",
        "designation",
        "tafamidis",
        "treatment",
        "patient",
        "transthyretin",
        "cardiomyopathy",
        "pfizer",
        "inc",
        "decision",
        "supported",
        "topline",
        "result",
        "tafamidis",
        "phase",
        "transthyretin",
        "cardiomyopathy",
        "study",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}